Linagliptin meets diabetes endpoints

Boehringer Ingelheim GmbH (Ingelheim, Germany) said once-daily oral linagliptin met the primary endpoint in two Phase III trials to treat Type II diabetes. In 227 diabetics for whom metformin therapy is inappropriate, linagliptin significantly reduced HbA1c from baseline to week 18 vs. placebo. In 245 patients with inadequately controlled Type II diabetes, linagliptin as an add-on to sulfonylurea also significantly reduced HbA1c from baseline to week 18 vs. placebo. Data were presented at the European Association for the Study of Diabetes meeting in Stockholm. Boehringer said it plans to submit global regulatory applications for the xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor this year. ...